UNSPSC 51413205: Vardenafil

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C23H32N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UCE6F4125H, chemically known as 2-(2-ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3h-imidazo(5,1-f)(1,2,4)triazin-4-one but generally known as vardenafil, which bears US NIH Compound Identifier 110634. European Medicines Agency schedules Vardenafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20047.

UNSPSC 51413205 Vardenafil is a Commodity code covering prescription pharmaceuticals supplied to state and local health systems, emergency services, and pharmacy benefit programs. State and local governments procure vardenafil and related prescription medications through direct-supply contracts with manufacturers and authorized wholesalers, serving hospital systems, fire rescue services, Medicaid pharmacy programs, and employee health plans. The issuing bodies span city purchasing departments (fire rescue and emergency medical services), state health and human services agencies, and multistate cooperative purchasing alliances representing multiple jurisdictions. Work solicited under this code includes supply of specific medication line items with firm pricing, expiration-date guarantees, rapid fulfillment timelines, and compliance with FDA, cGMP, and Drug Supply Chain Security Act requirements.

Recent activity shows the code in use across Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an Invitation for Bid (IFB) on April 24, 2026 (bid 26P00188) for Advanced Life Support Medications to supply Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000; the solicitation named four specific medication line items including epinephrine and diltiazem, requiring nine-month minimum expiration dates, ten-day delivery, and one-year firm pricing with optional renewal periods, and included a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Minnesota Department of Administration, through the Multistate Cooperative Purchasing Alliance (MMCAP), issued a Request for Proposal (RFP) posted January 20, 2026 with a response deadline of March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract awards effective July 1, 2026 and a two-year initial term. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to solicit vendor capabilities for a Direct-to-Manufacturer Prescriptions program serving the state's self-insured pharmacy benefit plans, indicating early-stage procurement development with no dollar commitment disclosed at the RFI stage.